An Open-label, Multicenter, Phase 2 Trial Investigating Sym004 in Patients With Metastatic Colorectal Cancer and Acquired Resistance to Anti-EGFR Monoclonal Antibodies and Documented Mutation of Extra Cellular Domain of EGFR (ECD-EGFR)
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2017
At a glance
- Drugs Futuximab/modotuximab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Sponsors Symphogen
- 17 Jan 2017 Status changed from recruiting to withdrawn prior to enrolment.
- 06 Jan 2017 This trial was completed in Spain, according to European Clinical Trials Database.
- 05 Jan 2017 Status changed from not yet recruiting to recruiting.